Infliximab is a monoclonal antibody used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. It works by inhibiting tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in the inflammatory response. By blocking TNF-α, Infliximab reduces inflammation and alleviates symptoms associated with these conditions. Common side effects may include infusion reactions and increased risk of infections, but these usually resolve with time. In summary, Infliximab is an effective treatment for various autoimmune diseases.
Infliximab binds to TNF-α, preventing it from interacting with its receptors, thereby inhibiting the inflammatory response mediated by TNF-α.